Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects.
Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects.
复制标题
多次大剂量鼠单克隆抗体CO17-1A的I期试验。
DOI：
10.1093/jnci/80.12.932
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
Wheeler,RH
中科院分区：
文献类型：
--
作者：
LoBuglio,AF;Saleh,MN;Lee,J;Khazaeli,MB;Carrano,R;Holden,H;Wheeler,RH
25例转移性胃肠道腺癌患者接受1至4次（400 mg）小鼠单克隆抗体CO17-1A输注。11名患者有轻微的胃肠道症状，1名患者有短暂的潮红发作。每周输注3次的5名患者中有2名在第三次输注时（第15天）出现了容易逆转的过敏反应。没有其他的毒性作用。一名患者病情完全缓解，存活了104周，另外四名患者病情稳定。整个组的中位生存期为57周。总的来说，抗体输注耐受性良好，但抗肿瘤作用有限。[J] contemporary medicine; 2009；80:932 - 936]
Twenty-five patients with metastatic gastrointestinal adenocarcinoma received one to four infusions (400 mg) of murine monoclonal antibody CO17-1A. Eleven patients had mild gastrointestinal symptoms, and one had a transient flushing episode. Two of five who received three weekly infusions had readily reversible anaphylactic reactions at the time of the third infusion (day 15). There were no other toxic effects. One patient had a complete remission and is surviving at >104 weeks, and four had stable disease. The median survival for the whole group was 57 weeks. In general, the antibody infusions were well tolerated but had modest antitumor effects. [J Natl Cancer Inst 1988; 80:932–936]